血清高尔基体蛋白73在原发性肝癌中的表达及早期诊断意义

目的探讨血清高尔基体蛋白73(GP73)在原发性肝癌(primary hepatic carcinoma,PHC)患者血清中的表达及其临床意义。方法采用酶联免疫吸附试验(ELISA)检测我院收治的47例PHC(肝癌组)及40例肝硬化(肝硬化组)血清中GP73,同时用电化学发光法检测血清甲胎蛋白(AFP),并将检测结果进行对比。结果 GP73和AFP测定值肝癌组分别为(220.44±89.71)μg/L、(404.06±135.43)μg/L,肝硬化组分别为(112.67±34.89)μg/L、(71.17±16.24)μg/L,组间比较差异均有统计学意义(t=93.485,t=250.924;P均<0.001)。GP73和AFP阳性率肝癌组分别为85.11%(40/47)、61.70%(29/47),肝硬化组分别为15.00%(6/40)、22.50%(9/40),组间比较差异均有统计学意义(χ2=70.654,χ2=31.284;P均<0.001)。肝癌组GP73异常与合并肝硬化或淋巴结转移有关(t=2.061,t=2.133;P均<0.05),与肿瘤大小及临床分期无关(t=0.560,t=0.573;P均>0.05)。结论肝癌患者血清高表达GP73,可能与肝癌的发生、发展有关,检测GP73有助于PHC早期诊断。     

高尔基体蛋白GP73在肝癌诊断中的临床意义

目的 定量检测样本血清中高尔基体蛋白73(GP73)的水平,同时对比GP73与甲胎蛋白(AFP)的检出,探讨GP73用于肝癌诊断的临床意义.方法 收集肝癌患者、肝炎及肝硬化、其他癌症以及健康人员样本,分别检测GP73和AFP,GP73检测采用酶联免疫定量测定,AFP检测用电化学发光法.结果 在186例肝癌标本中,GP73阳性率76.34%,AFP阳性率41.94%,经过χ2检验,两者差异有统计学意义(χ2=22.78,P<0.01);在肝炎及肝硬化患者和其他肿瘤患者中的GP73阳性检出率分别为10.66%和6.41%;AFP的阳性检出率分别为26.23%和26.92%,经过χ2检验,两者的检出率差异具有统计学意义(P<0.05);在健康人员中,GP73和AFP的检测特异性均为100%;ROC曲线分析显示,GP73和AFP的曲线下面积分别为0.932和0.770.结论 GP73用于诊断肝癌效果明显优于AFP,可以显著提高对肝癌诊断的灵敏度和特异性,而且GP73相比AFP更不容易受到肝部炎性反应和其他部位肿瘤的影响.     

高尔基体蛋白73及其基因检测对原发性肝癌诊断的价值

目的 评价分析GP73和GP73 mRNA在PHC中的诊断价值,探讨血清中GP73和AFP联合检测对PHC诊断和高危人群普查的意义,为PHC诊断和普查提供一种新方法 .方法 采用ELISA对73例PHC、13例肝硬化、32例肝炎和62名健康人的血清GP73、AFP水平进行检测,采用SYBR Green实时荧光定量PCR法检测各组外周血单个核细胞GP73 mRNA的相对表达量,以Ct值比较法计算GP73 mRNA相对表达水平,同时检测分析8份正常肝组织和8份肝癌组织的GP73 mRNA相对表达水平.结果 ELISA检测4组血清GF73、AFP结果 显示,总体比较经Kruskal-Wallis检验,4组间差异有统计学意义(H值分别为89.6、52.0,P均＜0.01),全血GP73 mRNA含量4组间差异无统计学意义(H=4.33,P＞0.05).组间多重比较Mann-Whitney检验结果显示,PHC组血清GP73的含量[166.7(162.7-231.8)μL]与肝硬化[57.3(46.6～113.6)μg/L]、肝炎[29.6(26.2～54.5)μg/L]及健康对照组[25.1(20.8～29.4)μg/L]比较,差异有统计学意义(U值分别为246、297、349,P均＜0.01),各组血清AFP的含量分别为380.9(258.5～ 503.2)μg/L、3.8(1.3～14.5)μg/L、5.1(2.4～7.8)μg/L、2.8(2.2～5.7)μg/L,差异亦有统计学意义(U值分别为246、419、790,P均＜0.01).肝癌组织GP73 mRNA表达量(12.64)显著高于正常肝组织(1.00).以ROC曲线确定诊断PHC的GP73临界值为123.2μg/L和AFP临界值为10.6 μg/L时,PHC组血清GP73、AFP单项检测的敏感度分别为65.8%和53.4%,特异度分别为95.3%和92.5%,两者联合检测的敏感度为79.5%,特异度为90.7%.结论 GP73蛋白对PHC诊断具有较好的敏感度和特异度;全血标本GP73 mRNA检测不能作为诊断PHC的肿瘤标志,肝组织标本GP73 mRNA检测可作为诊断PHC的肿瘤标志,但存在创伤性大、风险大、患者痛苦等缺点.血清GP73联合AFP检测可有效提高PHC诊断,可用于PHC高危人群的普查及筛选.     

高尔基体蛋白73及其基因检测对原发性肝癌诊断的价值

Objective To explore the diagnostic value of GP-/3 protein in gene detection in the patient of primary hepatic carcinoma, to discuss the joint roles of serum GP73 and AFP, and provide a novel method for the diagnosis for PHC and screening for high-risk population. Methods ELISA was used to detect the serum level of GP73 and AFP in 73 cases of PHC, 13 cases of hepatic cirrhosis, 32 cases of hepatitis and 62 cases of health people. SYBR Green real time fluorescence quantitative PCR was used to detect the relative value of GP73 mRNA in the peripheral blood cells of each group. Comparative Ct method was used to evaluate the relative expression levels. Eight cases of normal liver tissues and 8 cases of PHC tissues were detected at the same time to compare the relative expression levels. Results Kruskal-Wallis test showed that the serum levels of GP73 and AFP had significant differences between four groups(H value were 89. 6 and 52.0, P ＜ 0. 01) and the whole blood GP73 mRNA had no significant differences(H =4. 33, P ＞ 0. 05). Mann-Whitney test showed that the serum levels of GP73 had significant differences among PHC groups[166. 7 (162. 7-231.8) μg/L] and liver cirrhosis[57. 3 (46. 6-113. 6) μg/L], hepatitis[29. 6(26. 2-54. 5) μg/L], health group[25.1 (20. 8-29. 4) μg/L] (U value were 246, 297, 349, P ＜ 0. 01).The A FP levels of the four groups were 380. 9 (258.5-503.2) μg/L, 3.8 (1.3-14. 5) μg/L, 5. 1 (2. 4-7. 8)μg/L and 2. 8(2. 2-5.7) μg/L. It also showed significant differences (U value were 246,419 and 790,P ＜0. 01). The GP73 mRNA expression of PHC liver tissues(12. 64) was significant higher than normal liver tissues (1.00). The critical values for GP73 and AFP was determined to be 123. 2 μg/L and 10. 6 μg/L through the 8OC curves. Under the critical value the sensitivity of GP73 and AFP were 65.8% and 53.4% ,and the specificity of CP73 and AFP were 95.3% and 92. 5% respectively. Joint detection could increase the sensitivity up to 79. 5%, and achieve the high specificity of 90. 7%. Conclusions As a new diagnositic marker of primary hepatic carcinoma, GP73 protein has the very good sensitivity and specificity. The GP73 mRNA in the whole blood sample could not be used for the diagnosis of PHC. But it woule be a good molecular marker for diagnosis of PHC in the liver tissue sample. The joint detection of GP73 and AFP could improve PHC diagnostic performance, and provide an effective approcach to the PHC high-risk screening.     

高尔基体蛋白73及其基因检测对原发性肝癌诊断的价值

Objective To explore the diagnostic value of GP-/3 protein in gene detection in the patient of primary hepatic carcinoma, to discuss the joint roles of serum GP73 and AFP, and provide a novel method for the diagnosis for PHC and screening for high-risk population. Methods ELISA was used to detect the serum level of GP73 and AFP in 73 cases of PHC, 13 cases of hepatic cirrhosis, 32 cases of hepatitis and 62 cases of health people. SYBR Green real time fluorescence quantitative PCR was used to detect the relative value of GP73 mRNA in the peripheral blood cells of each group. Comparative Ct method was used to evaluate the relative expression levels. Eight cases of normal liver tissues and 8 cases of PHC tissues were detected at the same time to compare the relative expression levels. Results Kruskal-Wallis test showed that the serum levels of GP73 and AFP had significant differences between four groups(H value were 89. 6 and 52.0, P ＜ 0. 01) and the whole blood GP73 mRNA had no significant differences(H =4. 33, P ＞ 0. 05). Mann-Whitney test showed that the serum levels of GP73 had significant differences among PHC groups[166. 7 (162. 7-231.8) μg/L] and liver cirrhosis[57. 3 (46. 6-113. 6) μg/L], hepatitis[29. 6(26. 2-54. 5) μg/L], health group[25.1 (20. 8-29. 4) μg/L] (U value were 246, 297, 349, P ＜ 0. 01).The A FP levels of the four groups were 380. 9 (258.5-503.2) μg/L, 3.8 (1.3-14. 5) μg/L, 5. 1 (2. 4-7. 8)μg/L and 2. 8(2. 2-5.7) μg/L. It also showed significant differences (U value were 246,419 and 790,P ＜0. 01). The GP73 mRNA expression of PHC liver tissues(12. 64) was significant higher than normal liver tissues (1.00). The critical values for GP73 and AFP was determined to be 123. 2 μg/L and 10. 6 μg/L through the 8OC curves. Under the critical value the sensitivity of GP73 and AFP were 65.8% and 53.4% ,and the specificity of CP73 and AFP were 95.3% and 92. 5% respectively. Joint detection could increase the sensitivity up to 79. 5%, and achieve the high specificity of 90. 7%. Conclusions As a new diagnositic marker of primary hepatic carcinoma, GP73 protein has the very good sensitivity and specificity. The GP73 mRNA in the whole blood sample could not be used for the diagnosis of PHC. But it woule be a good molecular marker for diagnosis of PHC in the liver tissue sample. The joint detection of GP73 and AFP could improve PHC diagnostic performance, and provide an effective approcach to the PHC high-risk screening.     

血清高尔基体蛋白73和甲胎蛋白在肝细胞肝癌诊断中价值

目的探讨血清高尔基体蛋白73（Golgi protein 73,GP73）和甲胎蛋白（alpha—fetoprotein,AFP）对肝细胞肝癌（hepatocellular carcinoma,HCC）的诊断价值。方法150例HCC患者为HCC组,108例慢性肝炎患者为慢性肝炎组,100例体检健康者为对照组,采用双抗体夹心酶联免疫法检测3组血清GP73水平,采用电化学发光免疫分析法检测AFP水平。结果HCC组血清GP73（212．8（87．0,279．1）μg／L）、AFP（5212．8（1587,22279．1）μg／L）水平高于慢性肝炎组（55．3（27．0,83．2）μg／L和3．5（1．7,15．5）μg／L）和对照组（52．9（17．0,80．4）μg／L和2．9（1．5,14．7）μg／L）（P均〈0．05）;HCC组GP73、AFP阳性率分别为69％和70％,二者联合检测诊断HCC的敏感性为83％。结论血清GP73在HCC中高表达,可鉴别肝脏的良、恶性疾病,与AFP联合检测可提高检出率。     

血清高尔基体蛋白73在肝癌高风险人群中的诊断价值

目的 定量检测肝癌、肝硬化患者及健康者血清中高尔基体蛋白73(GP73)和甲胎蛋白(AFP)含量,探讨GP73在肝癌高风险人群的早期诊断价值.方法 采用酶联免疫法(ELISA)定量检测血清GP73,采用Roche电化学发光法定量检测AFP,并对实验数据进行统计学比较(χ2检验)和ROC分析.结果 (1)在127例肝癌血清标本中,GP73的阳性率为77.2%,AFP的阳性率47.0%,经t检验,两者差异有统计学意义(χ2=24.18,P<0.01).(2)在231例非肝癌患者中,GP73的诊断特异性为95.2%(220/231),AFP的诊断特异性为83.9%(194/231);(3)ROC曲线分析显示,GP73和AFP的曲线下面积分别为0.89和0.73.结论 GP73用于肝癌患者临床检测时,显著提高了诊断肝癌的灵敏度和特异性,效果明显优于AFP.     

血清GP73检测在原发性肝癌诊断中的价值

目的探讨血清中高尔基体蛋白73(GP73)对原发性肝癌(PHC)诊断的临床意义。方法应用ELISA法和化学发光免疫分析法分别对85例肝细胞癌、57例慢性肝炎、48例肝硬化和30例健康对照者血清中GP73及AFP进行定量检测。结果 GP73和AFP检测在肝癌组对PHC诊断的敏感度分别78.83%和64.71%;两者联合检测敏感度可提高至92.94%。结论 GP73对PHC诊断具有较好的敏感度,GP73和AFP联合诊断更有利于提高PHC的临床诊断。     

血清高尔基体蛋白73在肝细胞肝癌早期诊断中的价值

目的探讨血清高尔基体蛋白73(GP73)在肝细胞肝癌(HCC)早期诊断中的价值。方法分别检测57例HCC患者、71例肝硬化患者、82例乙型肝炎病毒(HBV)携带者和60例健康人的血清GP73水平及血清甲胎蛋白(AFP)水平,计算受试者工作特征曲线(ROC)下面积及对HCC诊断的敏感性与特异性。结果 HCC组中血清GP73水平显著高于健康对照组(P<0.05),肝硬化组、HBV携带者组血清GP73水平也有一定程度升高,但明显低于HCC组,差异均有统计学意义(P<0.05)。通过ROC曲线确定诊断HCC的血清GP73的cut-off值为100.18μg/L,在此临界值下GP73诊断HCC的敏感度和特异度分别为86.0%和93.9%;AFP诊断HCC的cut-off值为37.05μg/L,其诊断HCC的敏感度和特异度分别为77.2%和91.5%。二者联合检测HCC的敏感度为91.2%,特异度为92.5%。血清AFP浓度小于400μg/L的21例HCC患者中,有16例患者(76.19%)血清GP73水平高于临界值。结论 GP73高表达于HCC患者的血清中,对HCC诊断具有较好的敏感性与特异性,可作为肝癌早期诊断的血清标志物,与AFP联合检测可有效提高肝癌诊断的敏感度,特别有助于AFP阴性的肝癌患者的诊断。     

高尔基体蛋白73对中国人群肝癌诊价值的Meta分析

目的 评价高尔基体蛋白73（golgi protein 73,GP73）检测在肝癌诊断中的价值.方法 检索万方、中国知网、NCBI PubmMed,EMBSASE数据库中2000-2013年符合纳入标准的国内外公开发表的有关以血清GP73诊断中国人肝癌的文献8篇,采用meta-disc1.4软件进行统计软件分析.结果 GP73诊断肝癌敏感度为78％,95％可信区间为0.74-0.81;特异度为75％,95％可信区间为0.73-0.78;阳性预测值为5.07,95％可信区间为2.95-8.72;阴性预测值为0.29,95％可信区间为0.23-0.37;诊断优势比为18.98,95％可信区间为8.46-42.54;综合SROC曲线下面积（AUC）为0.86,Q值为0.79.结论 GP73作为肝癌肿瘤标志物在肝癌的诊断中有一定价值.     

血清GP73及AFP-L3检测在原发性肝癌诊断中的意义

目的探讨高尔基体蛋白73(GP73)及甲胎蛋白异质体(AFP-L3)在原发性肝癌(PHC)诊断中的应用价值。方法分别采用酶联免疫吸附试验和亲和吸附法法检测68例PHC患者、42例肝硬化患者以及40例健康体检者血清GP73以及AFP-L3的含量,计算AFP-L3占总AFP的比率。结果检测血清GP73诊断PHC的临界值为123.8μg/L,曲线下面积为0.909,95%可信区间为0.835～0.957,诊断灵敏度为72.1%,特异度为91.4%;血清AFP-L3诊断PHC临界值为10.53%,曲线下面积0.885,95%可信区间为0.826～0.940,诊断灵敏度为70.6%,特异度为93.9%;PHC组血清GP73及AFP-L3含量明显高于肝硬化组及对照组(P<0.05)。与GP73及AFP-L3单项检测比较,二者联合检测可明显提高PHC诊断的灵敏度、阴性预测值以及总有效率(P<0.05),而特异度和阳性预测值无显著性差异(P>0.05)。结论 GP73及AFP-L3含量在PHC患者血清中明显增高,且二者联合检测可提高PHC诊断效率,可作为PHC诊断的血清标志物。     

乙型肝炎肝硬化与肝癌患者HBV DNA、AFP-L3、GP73的差异及HBV DNA与AFP-L3、GP73相关性分析

目的探讨乙型肝炎肝硬化与肝癌患者乙型肝炎病毒DNA(HBV DNA)、血清甲胎蛋白异质体L3(AFP-L3)、高尔基蛋白73(GP73)的差异及HBV DNA与AFP-L3、GP73相关性。方法回顾该院2015年10月至2017年10月收治的乙型肝炎肝硬化患者和肝癌患者的临床资料,其中80例乙型肝炎肝硬化患者设为对照组,68例肝癌患者设为观察组。所有患者均采用PCR法检测血清HBV DNA,采用酶联免疫吸附法检测血清AFP-L3、GP73水平。比较两组患者血清HBV DNA、AFP-L3、GP73表达水平及阳性率的差异,采用Pearson相关对HBV DNA、AFP-L3、GP73相关性进行分析,并采用ROC曲线分析HBV DNA与AFP-L3、GP73在肝癌诊断中的价值。结果观察组患者HBV DNA、GP73表达阳性率高于对照组,但差异无统计学意义(P>0.05);观察组患者AFP-L3表达阳性率明显高于对照组,差异有统计学意义(χ2=55.01,P<0.001)。观察组患者血清HBV DNA、AFP-L3、GP73水平明显高于对照组,差异均有统计学意义(P<0.05)。分别将患者HBV DNA水平与AFP-L3、GP73水平作Pearson相关性分析,结果显示,HBV DNA与AFP-L3无相关性(r=0.214,P=0.079);HBV DNA与GP73表达无相关性(r=0.155,P=0.208)。采用ROC曲线对两组患者3种指标的鉴别诊断价值进行分析,3种指标均有一定的临床诊断价值(AUC>0.5),且AFP-L3在鉴别诊断中的应用价值最高(AUC=0.971,95%CI:0.943~0.999)。结论乙型肝炎肝硬化与肝癌患者HBV DNA、AFP-L3、GP73的水平存在明显差异,且肝癌患者血清HBV DNA与AFP-L3、GP73水平无明显相关性,AFP-L3在乙型肝炎肝硬化与肝癌的鉴别诊断中价值最高,值得在临床推广应用。     

AFP和GP73检测对肝硬化患者癌变的预警价值

目的探讨甲胎蛋白(AFP)、高尔基体蛋白73(GP73)对肝硬化患者肝癌发生风险的预警价值。方法采用化学发光法和酶联免疫吸附法分别检测AFP和GP73水平,对50例肝硬化患者进行跟踪随访24个月,了解肝癌发生情况,分析比较AFP、GP73预测肝硬化患者发生肝癌风险的价值。结果肝硬化患者随访18、24个月GP73(+)的癌变率显著高于AFP(+),差异有统计学意义(P0.05)。结论 AFP、GP73对肝硬化癌变均有预测价值,且GP73更具有预警价值。     

乙型肝炎合并肝硬化患者血清GP73变化特征及临床意义

目的明确慢乙型肝炎患者血清GP73变化特征及可能的临床意义。方法观察了109例慢乙型肝炎肝硬化患者血清GP73水平及可能的相关因素,其中代偿期肝硬化患者60例,失代偿肝硬化患者49例。对血清GP73鉴别代偿性及失代偿性肝硬化的诊断性能进行了受试者工作特征曲线(ROC)分析。结果慢乙型肝炎肝硬化患者血清GP73与血清丙氨酸氨基转移酶(ALT)、乙型肝炎病毒拷贝数(HBV DNA)水平显著相关,但与患者血清清蛋白水平呈显著负相关。失代偿性肝硬化患者[(215.9±96.56)ng/mL]血清GP73水平显著高于代偿期肝硬化患者[(113.7±68.95)ng/mL]。ROC分析结果显示,曲线下面积为0.82(95%CI:0.74~0.90,P0.05)。当cut-off值设定为大于或等于140.5ng/mL时,在乙型肝炎肝硬化患者人群中,GP73诊断失代偿期肝硬化的灵敏度和特异度分别为77.55%和75.00%。结论慢性乙型肝炎合并肝硬化患者血清GP73水平与肝损伤及病毒复制状态有关。检测血清GP73有助于肝硬化代偿与失代偿期之间的鉴别。     

肝细胞癌患者血清 GP73检测的临床价值

目的：探讨血清 GP73检测在肝细胞癌（HCC）诊断中的临床应用价值。方法应用酶联免疫吸附试验（ELISA）定量测定52例健康者、45例非肝性疾病患者、43例乙型病毒性肝炎患者、20例肝硬化患者和30例 HCC 患者血清标本中 GP73蛋白的表达水平;采用电化学发光法（ECL）检测 HCC 患者血清 AFP 水平,计算 ROC 曲线下面积及 GP73和 AFP 对 HCC 诊断的敏感度和特异性。结果非肝性疾病组（58．57±35．64）ng/mL、乙型肝炎组（70．36±49．88）ng/mL 和肝硬化组（114．47±51．27）ng/mL 以及 HCC 组（251．37±95．6）ng/mL 患者血清中的 GP73水平显著高于健康对照组（34．03±15．20）ng/mL,差异均有统计学意义（P ＜0．05）;HCC 组血清 GP73水平非常显著高于其他各组,差异均有统计学意义（P ＜0．01）;HCC 组血清 GP73的阳性检测率（76．7％）显著高于非 HCC 组（3．12％）,差异有统计学意义（χ2＝108,P ＜0．05）;GP73诊断 HCC 敏感度（75．1％）和特异性（94．9％）均高于 AFP 的敏感度（52．3％）和特异性（86．6％）。结论 GP73可能成为 HCC 诊断的一个更好的血清标志物。     

血清甲胎蛋白异质体、高尔基体糖蛋白-73及甲胎蛋白检测在老年人原发性肝癌的诊断价值

目的探讨血清甲胎蛋白异质体(AFP-L3)、高尔基体糖蛋白-73(GP73)及甲胎蛋白(AFP)检测在老年人原发性肝癌(HCC)的诊断价值。 方法研究对象为2014年1月至2016年3月就诊于福建医科大学附属第二医院普外科年龄>60岁的老年患者,共80例;其中HCC组40例,肝良性肿瘤组21例,肝硬化组19例。采用双抗体夹心酶联免疫吸附测定(ELISA)法检测血清GP73水平,电化学发光法检测血清AFP和AFP-L3水平,微量离心柱法分离AFP-L3,并计算甲胎蛋白异质体比例(AFP-L3%)。绘制受试者工作特征曲线(ROC),分析AFP、AFP-L3、AFP-L3%、GP73单独用于HCC鉴别诊断效果。所有入组患者均签署知情同意书,经医院伦理委员会研究通过。 结果各组间血清AFP、AFP-L3、AFP-L3%、GP73水平差异有统计学意义(F＝213.04,151.98,231.80,657.04;P<0.01)。HCC组血清AFP、AFP-L3、AFP-L3%、GP73水平[(681.41±195.56)μg/L,(138.11±44.00)μg/L,(15.31±3.28)%,(158.18±14.78)μg/L]高于肝良性肿瘤组[(7.94±3.50)μg/L,(0.41±0.28)μg/L,(3.58±0.51)%,(49.26±8.76)μg/L],差异具有统计学意义(q＝22.41,22.21,25.18,47.34;P<0.01);HCC组高于肝硬化组[(64.19±33.59)μg/L,(3.94±2.91)μg/L,(4.23±0.71)%,(46.88±11.64)μg/L],差异具有统计学意义(q＝25.18,23.56,27.72,47.63;P<0.01)。ROC曲线下面积分别为0.744,0.799,0.720,0.875;GP73曲线下面积最大。AFP诊断HCC敏感度及特异度为62.5%、80.0%,AFP-L3诊断HCC敏感度及特异度为70.0%、77.5%,GP73诊断HCC敏感度及特异度为90.0%、70.0%。AFP与AFP-L3联合检测后敏感度为86.7%,特异度为95.5%;AFP与GP73联合检测后敏感度为96.3%,特异度为95.5%;AFP-L3与GP73联合检测后敏感度为97.0%,特异度为93.3%。 结论GP73、AFP-L3有望成为新的诊断原发性肝癌的血清标志物,血清AFP-L3、GP73、AFP联合检测联合应用能弥补单项血清标志物的不足,对提高老年HCC的诊断具有一定价值。     

GP73, a new marker for diagnosing HBV-ACLF in population with chronic HBV infections

Although Golgi protein 73 (GP73) has been widely evaluated for diagnosing hepatocellular carcinoma (HCC) and other liver diseases in recent decade, its serum profile of patients with hepatitis B virus (HBV)–associated acute-on-chronic liver failure (HBV-ACLF) is still unknown. This study was designed to evaluate the serum levels of GP73 in patients with HBV-ACLF. The participants included 200 apparently healthy controls; 200 patients with chronic hepatitis B (CHB); 200 patients with HCC; 210 patients with HBV-ACLF, in which 29 HBV-ACLF patients were followed up for 3 months. All patients were Hepatitis B virus surface antigen (HBsAg) positive. The concentrations of GP73 in patients with HBV-ACLF (285.3 ± 128.5 ng/mL) were markedly higher than those HCC patients (159.1 ± 105.8 ng/mL), CHB patients (64.65 ± 44.99 ng/mL), and healthy controls (35.37 ± 12.41 ng/mL). When the cut-off value was set at 182.1 ng/mL, the sensitivity and specificity of HBV-ACLF diagnosis were 77.62% (95% confidence interval [CI]: 71.37%–83.07%) and 95.50% (95% CI: 92.27%–98.26%), respectively. If serum GP73 concentration was still above 361.6 ng/mL after 14 days of follow-up, the patient's prognosis may be depressed. Serum GP73 may be used to diagnosis HBV-ACLF in population with chronic HBV infections.